Thu, November 4, 2010
Wed, November 3, 2010
Tue, November 2, 2010
Mon, November 1, 2010
Sat, October 30, 2010
Fri, October 29, 2010
Thu, October 28, 2010
Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ] - Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010

Incyte to Report Third Quarter 2010 Financial Results and Provide Update on Drug Discovery & Development Programs on November 9


//health-fitness.news-articles.net/content/2010/ .. iscovery-development-programs-on-november-9.html
Published in Health and Fitness on Tuesday, October 26th 2010 at 13:20 GMT by Market Wire   Print publication without navigation


WILMINGTON, Del.--([ BUSINESS WIRE ])--Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2010 financial results conference call for 8:30 a.m. ET on Tuesday, November 9, 2010. The schedules for the press release and conference call are as follows:

-- Q3 2010 Press Release: November 9, 2010 at 7:00 a.m. ET
-- Q3 2010 Conference Call: November 9, 2010 at 8:30 a.m. ET
-- Domestic Dial In Number: 877-407-8037
-- International Dial In Number: 201-689-8037
-- Conference ID # 359419

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and dial-in number for international callers is 201-612-7415. To access the replay you will need the conference account number 278 and the ID number 359419.

The conference call will also be webcast live on CCBN and can be accessed at [ www.incyte.com ] under Investor Relations, Events and Webcasts.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation. Incytea™s most advanced compound, INCB18424, is in Phase III development for myelofibrosis and polycythemia vera. For additional information on Incyte, visit the Company's web site at [ www.incyte.com ].


Publication Contributing Sources